CoChat

Management of antipsychotic-related weight gain

Open access
Maayan, Lawrence, Correll, Christoph U · 2010 · Expert Review of Neurotherapeutics
Cited by 128

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Despite variations across individuals and agents, antipsychotics are associated with clearly documented weight gain and adverse metabolic effects. Although increased appetite/caloric intake and various receptors, hormones and peptides have been implicated, biological mechanisms contributing to the increase in weight and glucose and lipid abnormalities with antipsychotics are largely unknown. This has hampered the creation of antipsychotics that are free of cardiometabolic effects, even in antipsychotic-naive/early-phase patients, as well as the development of strategies that can prevent or drastically diminish the adverse cardiometabolic effects. In general, three strategies can reduce the cardiometabolic risk of antipsychotics: switching to a less orexigenic/metabolically adverse antipsychotic; adjunctive behavioral treatments; and adjunctive pharmacologic interventions. However, each of these strategies has only been shown to be modestly effective. Among different behavioral interventions (N = 14, n = 746), group and individual treatment, dietary counseling and cognitive-behavioral therapy seem to be similarly effective. Among 15 different pharmacologic strategies (N = 35, n = 1629), only metformin, fenfluramine, sibutramine, topiramate and reboxetine were more effective than placebo, with the most evidence being available for metformin, and no head-to-head trials comparing individual pharmacologic interventions. However, even in the most successful trials the risk reduction was modest. Weight was not decreased to a pretreatment level, and despite superiority compared with placebo, weight gain still often occurred, particularly in antipsychotic-naive patients and when interventions were 'preventively' coinitiated with antipsychotics. Future research should focus on combining treatment modalities or agents and on exploring novel mechanism-based interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/ern.10.85

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 161

  1. 10.1377/hlthaff.28.5.w822 · DOI · Paper page
  2. 10.1016/S0920-9964(02)00498-X · DOI · Paper page
  3. Allison, 2003, Psychiatr. Serv., 54, 565, 10.1176/appi.ps.54.4.565 · DOI · Paper page
  4. 10.2165/00023210-200519001-00001 · DOI · Paper page
  5. 10.4088/JCP.v65n0219 · DOI · Paper page
  6. Kinon, 2005, J. Clin. Psychopharmacol., 25, 255, 10.1097/01.jcp.0000161501.65890.22 · DOI · Paper page
  7. 10.1016/S0140-6736(08)60486-9 · DOI · Paper page
  8. Ratzoni, 2002, J. Am. Acad. Child Adolesc. Psychiatry, 41, 337, 10.1097/00004583-200203000-00014 · DOI · Paper page
  9. 10.1176/appi.ajp.2008.08050756 · DOI · Paper page
  10. 10.1097/01.jcp.0000130558.86125.5b · DOI · Paper page
  11. Basson, 2001, J. Clin. Psychiatry, 62, 231, 10.4088/JCP.v62n0404 · DOI · Paper page
  12. Gebhardt, 2009, J. Psychiatr. Res., 43, 620, 10.1016/j.jpsychires.2008.11.001 · DOI · Paper page
  13. Lane, 2003, J. Clin. Psychiatry, 64, 316, 10.4088/JCP.v64n0314 · DOI
  14. 10.1097/01.jcp.0000203196.65710.2b · DOI
  15. Wetterling, 1999, J. Clin. Psychopharmacol., 19, 316, 10.1097/00004714-199908000-00006 · DOI
  16. Calarge, 2009, J. Child Adolesc. Psychopharmacol., 19, 101, 10.1089/cap.2008.007 · DOI · Paper page
  17. Neovius, 2007, Acta Psychiatr. Scand., 115, 277, 10.1111/j.1600-0447.2006.00899.x · DOI
  18. Weiss, 2009, J. Child Adolesc. Psychopharmacol., 19, 575, 10.1089/cap.2009.0050 · DOI · Paper page
  19. Correll, 2007, J. Am. Acad. Child Adolesc. Psychiatry, 46, 687, 10.1097/chi.0b013e318040b25f · DOI · Paper page
  20. Strassnig, 2007, Schizophr. Res., 93, 90, 10.1016/j.schres.2007.02.024 · DOI
  21. Gentile, 2009, Obes. Rev., 10, 527, 10.1111/j.1467-789X.2009.00589.x · DOI · Paper page
  22. Hummer, 1995, Eur. Neuropsychopharmacol., 5, 437, 10.1016/0924-977X(95)80001-I · doi:10.1016/0924-977x(95)80001-i
  23. Lee, 2004, J. Clin. Psychiatry, 65, 864, 10.4088/JCP.v65n0620 · DOI
  24. Saddichha, 2008, Schizophr. Res., 101, 266, 10.1016/j.schres.2008.01.004 · DOI
  25. 10.1016/j.psychres.2008.10.007 · DOI
  26. Lipkovich, 2008, BMC Psychiatry, 8, 78, 10.1186/1471-244X-8-78 · DOI
  27. Stauffer, 2009, BMC Psychiatry, 9, 12, 10.1186/1471-244X-9-12 · DOI
  28. Hennen, 2004, J. Clin. Psychiatry, 65, 1679, 10.4088/JCP.v65n1214 · DOI
  29. Simon, 2009, J. Clin. Psychiatry, 70, 1041, 10.4088/JCP.08r04392 · DOI · Paper page
  30. Reaven, 2009, J. Psychiatr. Res., 43, 997, 10.1016/j.jpsychires.2009.01.010 · DOI
  31. Ader, 2008, J. Psychiatr. Res., 42, 1076, 10.1016/j.jpsychires.2008.01.004 · DOI
  32. Houseknecht, 2007, Neuropsychopharmacology, 32, 289, 10.1038/sj.npp.1301209 · DOI · Paper page
  33. Mukherjee, 1989, Lancet, 1, 495, 10.1016/S0140-6736(89)91392-5 · DOI · Paper page
  34. Cohn, 2006, Can. J. Psychiatry, 51, 382, 10.1177/070674370605100608 · DOI
  35. Ryan, 2003, Am. J. Psychiatry, 160, 284, 10.1176/appi.ajp.160.2.284 · DOI · Paper page
  36. Spelman, 2007, Diabet. Med., 24, 481, 10.1111/j.1464-5491.2007.02092.x · DOI · Paper page
  37. Verma, 2009, J. Clin. Psychiatry, 70, 997, 10.4088/JCP.08m04508 · DOI
  38. Fernandez-Egea, 2009, Br. J. Psychiatry, 194, 434, 10.1192/bjp.bp.108.052605 · DOI · Paper page
  39. Meyer, 2009, Acta Psychiatr. Scand., 119, 4, 10.1111/j.1600-0447.2008.01317.x · DOI · Paper page
  40. 10.1016/j.schres.2005.07.014 · DOI · Paper page
  41. De Hert, 2006, Clin. Pract. Epidemiol. Ment. Health, 2, 14, 10.1186/1745-0179-2-14 · DOI
  42. Colton, 2006, Prev. Chronic Dis., 3, A42
  43. De Hert, 2009, Schizophr. Res., 117, 68, 10.1016/j.schres.2009.12.029 · DOI
  44. Arjona, 2004, Behav. Brain Res., 152, 121
  45. Gothelf, 2002, Am. J. Psychiatry, 159, 1055, 10.1176/appi.ajp.159.6.1055 · DOI · Paper page
  46. Graham, 2005, Am. J. Psychiatry, 162, 118, 10.1176/appi.ajp.162.1.118 · DOI · Paper page
  47. Zurlo, 1990, Am. J. Physiol., 259, E650
  48. Sharpe, 2006, Aust. N Z J. Psychiatry, 40, 810, 10.1080/j.1440-1614.2006.01888.x · DOI · Paper page
  49. Correll, 2004, Psychopharmacology (Berl.), 174, 477, 10.1007/s00213-004-1949-9 · DOI
  50. Sentissi, 2009, Int. Clin. Psychopharmacol., 24, 257, 10.1097/YIC.0b013e32832b6bf6 · DOI
  51. Ota, 2002, Clin. Exp. Pharmacol. Physiol., 29, 980, 10.1046/j.1440-1681.2002.t01-1-03755.x · DOI
  52. 10.1038/sj.npp.1300327 · DOI · Paper page
  53. 10.1097/00004583-200212000-00015 · DOI
  54. Newcomer, 2002, Arch. Gen. Psychiatry, 59, 337, 10.1001/archpsyc.59.4.337 · DOI · Paper page
  55. Henderson, 2005, Arch. Gen. Psychiatry, 62, 19, 10.1001/archpsyc.62.1.19 · DOI · Paper page
  56. Johnson, 2005, Diabetes, 54, 1552, 10.2337/diabetes.54.5.1552 · DOI · Paper page
  57. Reynolds, 2010, Pharmacol. Ther., 125, 169, 10.1016/j.pharmthera.2009.10.010 · DOI · Paper page
  58. Bai, 2009, Schizophr. Res., 111, 1, 10.1016/j.schres.2009.03.014 · DOI
  59. Maayan, 2010, Hum. Psychopharmacol., 25, 133, 10.1002/hup.1097 · DOI
  60. Haupt, 2005, Neuropsychopharmacology, 30, 184, 10.1038/sj.npp.1300563 · DOI
  61. Zhang, 2004, Br. J. Psychiatry, 184, 58, 10.1192/bjp.184.1.58 · DOI · Paper page
  62. Deng, 2010, Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 1, 10.1016/j.pnpbp.2009.11.009 · DOI
  63. 10.1038/sj.npp.1300027 · DOI · Paper page
  64. Kim, 2007, Proc. Natl Acad. Sci. USA, 104, 3456, 10.1073/pnas.0611417104 · DOI · Paper page
  65. 10.1016/j.pnpbp.2005.03.019 · DOI
  66. Mulder, 2007, Pharmacogenomics J., 7, 318, 10.1038/sj.tpj.6500422 · DOI
  67. De Luca, 2007, Hum. Psychopharmacol., 22, 463, 10.1002/hup.868 · DOI
  68. Templeman, 2005, Pharmacogenet. Genomics, 15, 195, 10.1097/01213011-200504000-00002 · DOI · Paper page
  69. Souza, 2008, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 1848, 10.1016/j.pnpbp.2008.08.014 · DOI
  70. Siffert, 1999, J. Am. Soc. Nephrol., 10, 1921, 10.1681/ASN.V1091921 · DOI · Paper page
  71. Lencz, 2009, Dialogues Clin. Neurosci., 11, 405, 10.31887/DCNS.2009.11.4/tlencz · DOI
  72. Tiwari, 2010, Neuropsychopharmacology, 35, 1315, 10.1038/npp.2009.235 · DOI
  73. Liu, 2010, Pharmacogenomics J., 10, 30, 10.1038/tpj.2009.55 · DOI
  74. 10.4088/JCP.0508e14 · DOI
  75. Pae, 2009, Eur. Neuropsychopharmacol., 19, 562, 10.1016/j.euroneuro.2009.04.002 · DOI
  76. Ganguli, 2008, BMC Med., 6, 17, 10.1186/1741-7015-6-17 · DOI
  77. Essock, 2006, Am. J. Psychiatry, 163, 2090, 10.1176/ajp.2006.163.12.2090 · DOI · Paper page
  78. Rosenheck, 2009, Schizophr. Res., 107, 22, 10.1016/j.schres.2008.09.031 · DOI · Paper page
  79. De Hert, 2007, Schizophr. Bull., 33, 823, 10.1093/schbul/sbl037 · DOI
  80. 10.1016/j.schres.2007.12.487 · DOI · Paper page
  81. Meyer, 2005, Clin. Ther., 27, 1930, 10.1016/j.clinthera.2005.12.005 · DOI
  82. 10.4088/JCP.v69n0702 · DOI · Paper page
  83. 10.1016/j.schres.2008.09.002 · DOI · Paper page
  84. Lin, 2009, J. Clin. Psychopharmacol., 29, 529, 10.1097/JCP.0b013e3181bf613e · DOI
  85. Ried, 2009, J. Am. Pharm. Assoc., 49, 223, 10.1331/JAPhA.2009.08151 · DOI
  86. Weiden, 2008, Neuropsychopharmacology, 33, 985, 10.1038/sj.npp.1301482 · DOI
  87. Casey, 2003, Psychopharmacology (Berl.), 166, 391, 10.1007/s00213-002-1344-3 · DOI · Paper page
  88. Montes, 2007, Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 383, 10.1016/j.pnpbp.2006.10.002 · DOI
  89. 10.1192/bjp.bp.107.042853 · DOI · Paper page
  90. Gabriele, 2009, Obes. Rev., 10, 442, 10.1111/j.1467-789X.2009.00570.x · DOI · Paper page
  91. Alvarez-Jimenez, 2006, J. Clin. Psychiatry, 67, 1253, 10.4088/JCP.v67n0812 · DOI · Paper page
  92. 10.1542/peds.2008-3727 · DOI · Paper page
  93. 10.1001/jama.264.19.2519 · doi:10.1001/jama.264.19.2519
  94. Johnston, 2007, J. Pediatr. Psychol., 32, 106, 10.1093/jpepsy/jsl010 · DOI
  95. 10.1097/01.chi.0000220851.94392.30 · DOI · Paper page
  96. Faulkner, 2007, Schizophr. Bull., 33, 654, 10.1093/schbul/sbm022 · DOI · Paper page
  97. Baptista, 2008, CNS Drugs, 22, 477, 10.2165/00023210-200822060-00003 · DOI
  98. Maayan, 2010, Neuropsychopharmacology, 35, 1520, 10.1038/npp.2010.21 · DOI · Paper page
  99. Baptista, 2006, Can. J. Psychiatry, 51, 192, 10.1177/070674370605100310 · DOI · Paper page
  100. Baptista, 2007, Schizophr. Res., 93, 99, 10.1016/j.schres.2007.03.029 · DOI
  101. Carrizo, 2009, Schizophr. Res., 113, 19, 10.1016/j.schres.2009.05.007 · DOI
  102. Wu, 2008, Am. J. Psychiatry, 165, 352, 10.1176/appi.ajp.2007.07010079 · DOI · Paper page
  103. Arman, 2008, Saudi Med. J., 29, 1130
  104. Klein, 2006, Am. J. Psychiatry, 163, 2072, 10.1176/ajp.2006.163.12.2072 · DOI · Paper page
  105. Citrome, 2008, Acta Psychiatr. Scand., 117, 412, 10.1111/j.1600-0447.2008.01194.x · DOI · Paper page
  106. 10.1016/j.braindev.2004.06.006 · DOI
  107. Roerig, 2009, Biol. Psychiatry, 65, 607, 10.1016/j.biopsych.2008.10.037 · DOI
  108. Gross, 2009, Adv. Ther., 26, 959, 10.1007/s12325-009-0070-1 · DOI
  109. Gross, 2010, Obesity (Silver Spring)
  110. 10.1001/jama.295.7.761 · DOI · Paper page
  111. Chakrabarti, 2009, Expert Opin. Ther. Targets, 13, 195, 10.1517/14728220802637063 · DOI
  112. Baptista, 2008, Psychiatry Res., 159, 250, 10.1016/j.psychres.2008.01.011 · DOI
  113. 10.4088/JCP.v65n0219 · DOI · Paper page
  114. 10.1093/schbul/ sbm038 · doi:10.1093/schbul/
  115. 10.1176/appi.ajp.2008.08030383 · DOI · Paper page
  116. Morrato, 2009, J. Clin. Psychopharmacol., 29, 26, 10.1097/JCP.0b013e31819294cb · DOI
  117. Morrato, 2010, Arch. Gen. Psychiatry, 67, 17, 10.1001/archgenpsychiatry.2009.179 · DOI · Paper page
  118. Morrato, 2008, J. Clin. Psychiatry, 69, 316, 10.4088/JCP.v69n0219 · DOI · Paper page
  119. 10.2337/dc08–1720 · DOI · Paper page
  120. Morrato, 2010, Arch. Pediatr. Adolesc. Med., 164, 344, 10.1001/archpediatrics.2010.48 · DOI · Paper page
  121. Le Foll, 2009, Psychopharmacology (Berl.), 205, 171, 10.1007/s00213-009-1506-7 · DOI · Paper page
  122. 10.4088/JCP.v66n0208 · DOI · Paper page
  123. Khazaal, 2007, Schizophr. Res., 91, 169, 10.1016/j.schres.2006.12.025 · DOI · Paper page
  124. Kwon, 2006, J. Clin. Psychiatry, 67, 547, 10.4088/JCP.v67n0405 · DOI · Paper page
  125. 10.1016/j.schres.2006.05.010 · DOI · Paper page
  126. 10.1016/j.schres.2006.01.008 · DOI
  127. 10.1080/00048670701689428 · DOI · Paper page
  128. Milano, 2007, Adv. Ther., 24, 123, 10.1007/BF02850000 · DOI
  129. 10.1176/ps.2007.58.4.544 · doi:10.1176/ps.2007.58.4.544 · Paper page
  130. Mauri, 2008, Pharmacopsychiatry, 41, 17, 10.1055/s-2007-992148 · DOI · Paper page
  131. Scocco, 2006, Eat. Behav., 7, 115, 10.1016/j.eatbeh.2005.08.003 · DOI
  132. Alvarez-Jimenez, 2010, Schizophr. Res., 116, 16, 10.1016/j.schres.2009.10.012 · DOI
  133. Evans, 2005, Aust. N Z J. Psychiatry, 39, 479
  134. 10.1111/j.1547-5069.2003.00237.x · DOI · Paper page
  135. 10.1016/j.euroneuro.2004.03.005 · DOI
  136. Modell, 1965, JAMA, 193, 275, 10.1001/jama.1965.03090040019006 · doi:10.1001/jama.1965.03090040019006
  137. Goodall, 1988, Br. J. Psychiatry, 153, 208, 10.1192/bjp.153.2.208 · DOI
  138. Bustillo, 2003, Neuropsychopharmacology, 28, 527, 10.1038/sj.npp.1300089 · DOI
  139. Assuncao, 2006, Rev. Bras. Psiquiatr., 28, 270, 10.1590/S1516-44462006000400005 · doi:10.1590/s1516-44462006000400005
  140. Atmaca, 2003, Hum. Psychopharmacol., 18, 457, 10.1002/hup.514 · DOI
  141. Atmaca, 2004, Hum. Psychopharmacol., 19, 37, 10.1002/hup.477 · DOI
  142. Joffe, 2008, J. Clin. Psychiatry, 69, 706, 10.4088/JCP.v69n0503 · DOI · Paper page
  143. Borovicka, 2002, J. Clin. Psychiatry, 63, 345, 10.4088/JCP.v63n0412 · doi:10.4088/jcp.v63n0412
  144. Baptista, 2009, Pharmacopsychiatry, 42, 14, 10.1055/s-0028-1085438 · DOI
  145. Henderson, 2009, Acta Psychiatr. Scand., 119, 457, 10.1111/j.1600-0447.2008.01325.x · DOI · Paper page
  146. Henderson, 2005, Am. J. Psychiatry, 162, 954, 10.1176/appi.ajp.162.5.954 · DOI
  147. Henderson, 2007, Acta Psychiatr. Scand., 115, 101, 10.1111/j.1600-0447.2006.00855.x · DOI
  148. Afshar, 2009, J. Psychopharmacol., 23, 157, 10.1177/0269881108089816 · DOI · Paper page
  149. Roy Chengappa, 2007, Bipolar Disord., 9, 609, 10.1111/j.1399-5618.2007.00506.x · DOI
  150. Ko, 2005, Clin. Neuropharmacol., 28, 169, 10.1097/01.wnf.0000172994.56028.c3 · DOI · Paper page
  151. Narula, 2010, Schizophr. Res., 118, 218, 10.1016/j.schres.2010.02.001 · DOI
  152. Nickel, 2005, J. Clin. Psychopharmacol., 25, 211, 10.1097/01.jcp.0000162806.46453.38 · DOI
  153. 10.1016/j.euroneuro.2003.10.004 · DOI
  154. 10.1176/appi.ajp.159.6.1058 · DOI
  155. Hinze-Selch, 2000, Psychopharmacology (Berl.), 149, 163, 10.1007/s002139900351 · DOI
  156. Lu, 2004, J. Clin. Psychiatry, 65, 766, 10.4088/JCP.v65n0607 · doi:10.4088/jcp.v65n0607
  157. Cavazzoni, 2003, Eur. Neuropsychopharmacol., 13, 81, 10.1016/S0924-977X(02)00127-X · DOI
  158. 10.1176/appi.ajp.160.2.297 · DOI · Paper page
  159. Poyurovsky, 2007, Psychopharmacology (Berl.), 192, 441, 10.1007/s00213-007-0731-1 · DOI
  160. Kim, 2006, Schizophr. Res., 82, 115, 10.1016/j.schres.2005.10.001 · DOI
  161. 10.1097/chi.0b013e31815b5cb1 · DOI · Paper page

Cited by

See all 128

Metadata

Authors
Maayan, L., & Correll, C. U.
Venue
Expert Review of Neurotherapeutics
Published
2010-07
Volume
10
Issue
7
Pages
1175-1200
ISSN
  • 1473-7175 (ISSN-L)
  • 1744-8360
OpenAlex
W2167683515
Cited by
128
References
18
FWCI
4.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.